191 related articles for article (PubMed ID: 23407853)
1. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Keskitalo JE; Kurkinen KJ; Neuvoneni PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):457-61. PubMed ID: 19238649
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Teng R; Mitchell PD; Butler KA
Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.
K P A; Meda VS; Kucherlapati VS; Dubala A; M D; P R AV; K E; B S
Eur J Clin Pharmacol; 2012 May; 68(5):709-14. PubMed ID: 22173280
[TBL] [Abstract][Full Text] [Related]
5. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
[TBL] [Abstract][Full Text] [Related]
6. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
7. Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.
Jensen BP; Roberts RL; Vyas R; Bonke G; Jardine DL; Begg EJ
Br J Clin Pharmacol; 2012 Apr; 73(4):619-28. PubMed ID: 21999196
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):745-58. PubMed ID: 22587686
[TBL] [Abstract][Full Text] [Related]
9. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Rao N; Dvorchik B; Sussman N; Wang H; Yamamoto K; Mori A; Uchimura T; Chaikin P
J Clin Pharmacol; 2008 Sep; 48(9):1092-8. PubMed ID: 18552277
[TBL] [Abstract][Full Text] [Related]
10. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
12. The effects of simvastatin on the pharmacokinectics of sitagliptin.
Cerra M; Luo WL; Li SX; Matthews C; O'Neill EA; Wagner JA; Stoch SA; Anderson MS
J Popul Ther Clin Pharmacol; 2012; 19(3):e356-60. PubMed ID: 23077137
[TBL] [Abstract][Full Text] [Related]
13. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study.
Kandhwal K; Dey S; Nazarudheen S; Arora R; Reyar S; Thudi NR; Monif T; Singh MK; Rao S
Clin Drug Investig; 2011 Dec; 31(12):853-63. PubMed ID: 21919543
[TBL] [Abstract][Full Text] [Related]
15. Combined Influence of Genetic Polymorphism and DNA Methylation on ABCB1 Expression and Function in Healthy Chinese Males.
Wu LX; Zhao HB; Wen CJ; Li Y; Shao YY; Yang Z; Zhou HH
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):627-634. PubMed ID: 27683186
[TBL] [Abstract][Full Text] [Related]
16. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
[TBL] [Abstract][Full Text] [Related]
17. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Shin J; Pauly DF; Pacanowski MA; Langaee T; Frye RF; Johnson JA
Pharmacotherapy; 2011 Oct; 31(10):942-50. PubMed ID: 21950641
[TBL] [Abstract][Full Text] [Related]
18. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
19. Effect of multidrug resistance gene-1 (ABCB1) polymorphisms on the single-dose pharmacokinetics of cloxacillin in healthy adult Chinese men.
Yin OQ; Tomlinson B; Chow MS
Clin Ther; 2009 May; 31(5):999-1006. PubMed ID: 19539100
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
